相似文献
1
Avidity assay to test functionality of anti-SARS-Cov-2 antibodies.
Vaccine. 2021 Mar 5;39(10):1473-1475. doi: 10.1016/j.vaccine.2021.02.003. Epub 2021 Feb 3.
2
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
3
Characterization of SARS-CoV-2-specific antibodies in COVID-19 patients reveals highly potent neutralizing IgA.
Signal Transduct Target Ther. 2021 Jan 29;6(1):35. doi: 10.1038/s41392-021-00478-7.
4
Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.
Hum Vaccin Immunother. 2021 Mar 4;17(3):654-655. doi: 10.1080/21645515.2020.1814098. Epub 2020 Sep 29.
5
Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.
J Allergy Clin Immunol. 2021 Mar;147(3):876-877. doi: 10.1016/j.jaci.2020.12.003. Epub 2020 Dec 17.
6
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.
7
Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2.
Front Immunol. 2021 Aug 30;12:715464. doi: 10.3389/fimmu.2021.715464. eCollection 2021.
8
Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
J Clin Invest. 2022 Feb 15;132(4). doi: 10.1172/JCI154987.
9
Neutralizing SARS-CoV-2.
Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.
10
Structure-based development of human antibody cocktails against SARS-CoV-2.
Cell Res. 2021 Jan;31(1):101-103. doi: 10.1038/s41422-020-00446-w. Epub 2020 Dec 1.
引用本文的文献
1
Evaluation of Efficacy of Surface Coated versus Encapsulated Influenza Antigens in Mannose-Chitosan Nanoparticle-Based Intranasal Vaccine in Swine.
Vaccines (Basel). 2024 Jun 11;12(6):647. doi: 10.3390/vaccines12060647.
2
Hybrid immunity in older adults is associated with reduced SARS-CoV-2 infections following BNT162b2 COVID-19 immunisation.
Commun Med (Lond). 2023 Jun 16;3(1):83. doi: 10.1038/s43856-023-00303-y.
3
COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response.
Front Microbiol. 2023 Apr 20;14:1117494. doi: 10.3389/fmicb.2023.1117494. eCollection 2023.
4
Binding and Avidity Signatures of Polyclonal Sera From Individuals With Different Exposure Histories to Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Vaccination, and Omicron Breakthrough Infections.
J Infect Dis. 2023 Aug 31;228(5):564-575. doi: 10.1093/infdis/jiad116.
5
The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity.
Med Microbiol Immunol. 2023 Jun;212(3):203-220. doi: 10.1007/s00430-023-00763-y. Epub 2023 Apr 27.
6
RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2.
Viruses. 2023 Feb 17;15(2):555. doi: 10.3390/v15020555.
7
SARS-CoV-2 vaccines: Potential refinements through induction of mucosal and trained immunity.
Clinics (Sao Paulo). 2022 May 30;77:100057. doi: 10.1016/j.clinsp.2022.100057. eCollection 2022.
8
Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection.
Viruses. 2022 Mar 16;14(3):617. doi: 10.3390/v14030617.
9
Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.
PLoS One. 2022 Feb 10;17(2):e0263328. doi: 10.1371/journal.pone.0263328. eCollection 2022.
10
Clinical Evaluation of Siemens SARS-CoV-2 Total Antibody assay and IgG assay using the Dimension EXL 200 in the Tokyo Metropolitan area.
Heliyon. 2021 Nov;7(11):e08393. doi: 10.1016/j.heliyon.2021.e08393. Epub 2021 Nov 16.
本文引用的文献
1
Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates.
Nat Biomed Eng. 2020 Dec;4(12):1188-1196. doi: 10.1038/s41551-020-00642-4. Epub 2020 Oct 29.
2
Immune response following infection with SARS-CoV-2 and other coronaviruses: A rapid review.
Rev Med Virol. 2021 Mar;31(2):e2162. doi: 10.1002/rmv.2162. Epub 2020 Sep 23.
3
SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
J Infect Dis. 2020 Nov 13;222(12):1974-1984. doi: 10.1093/infdis/jiaa581.
4
SARS-CoV-2 Assays To Detect Functional Antibody Responses That Block ACE2 Recognition in Vaccinated Animals and Infected Patients.
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.01533-20.
5
How Nanophotonic Label-Free Biosensors Can Contribute to Rapid and Massive Diagnostics of Respiratory Virus Infections: COVID-19 Case.
ACS Sens. 2020 Sep 25;5(9):2663-2678. doi: 10.1021/acssensors.0c01180. Epub 2020 Aug 24.
6
Immune responses of meningococcal B outer membrane vesicles in middle-aged mice.
Pathog Dis. 2020 Jul 1;78(5). doi: 10.1093/femspd/ftaa028.
7
The variability of the serological response to SARS-corona virus-2: Potential resolution of ambiguity through determination of avidity (functional affinity).
J Med Virol. 2021 Jan;93(1):311-322. doi: 10.1002/jmv.26262. Epub 2020 Jul 15.
8
Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays.
J Infect. 2020 Aug;81(2):e6-e10. doi: 10.1016/j.jinf.2020.04.033. Epub 2020 May 7.
9
Rapid COVID-19 vaccine development.
Science. 2020 May 29;368(6494):945-946. doi: 10.1126/science.abb8923. Epub 2020 May 8.
10
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.
Viruses. 2020 May 6;12(5):513. doi: 10.3390/v12050513.
Zotero 插件